Store the resin in 3 bed volumes of 1XPBS (20% ethanol) at 4C-30C to prevent bacterial pollution of the resin
More than half of colorectal cancers (CRCs) harbor activating mutations in KRAS or BRAF, yet those cancers are the most refractory to current targeted therapies
When they become too short, the cell can no longer divide and enters a state called senescence essentially, cellular aging
In: Scher RK, Daniel CR III, et al., editors
Vin ung trng da Damian chnh hng Dng trng da ton thn hiu qu
GLP-1 Receptor Agonist Market Report 2026 Global Outlook By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs), By Route Of Administration (Parenteral, Oral), By End Users (Hospitals, Surgical Clinics, Other Users) Market Size, Trends, Strategies, and Forecast to 2035 GLP-1 Receptor Agonist Market Overview GLP-1 Receptor Agonist market size has reached to $14.09 billion in 2025 Expected to grow to $18.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% Growth Driver: Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market Market Trend: Sustained-Release Glp-1 Receptor Agonists Are Gaining Popularity North America was the largest region in 2025 and Asia-Pacific is the fastest growing region
